Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Secretin is a peptide hormone produced primarily by S cells in the duodenum. As a drug, it is used diagnostically to stimulate pancreatic and gastric secretions for the evaluation of exocrine pancreatic function, diagnosis of gastrinoma (Zollinger-Ellison syndrome), and identification of abnormalities in the bile and pancreatic ducts during endoscopic procedures. Secretin acts as an agonist at G-protein coupled secretin receptor found on various tissues including the pancreas, stomach, liver, and colon. Its main mechanism is to stimulate secretion of bicarbonate-rich fluid from the pancreas to neutralize gastric acid in the duodenum; it also inhibits gastric acid secretion by parietal cells through multiple pathways. Secretin can be derived from porcine sources or produced synthetically (recombinant human). It has been explored for other indications such as autism and schizophrenia but lacks evidence for efficacy outside its approved diagnostic uses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on secretin.